AtriCure, Inc. (ATRC)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XFRA 
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings
The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
AtriCure, Inc. (ATRC) Q4 2025 Earnings Call Transcript
AtriCure, Inc. (ATRC) Q4 2025 Earnings Call Transcript
AtriCure (ATRC) Tops Q4 Earnings and Revenue Estimates
AtriCure (ATRC) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.08 per share a year ago.
Will AtriCure (ATRC) Report Negative Earnings Next Week? What You Should Know
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AtriCure, Inc. (ATRC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
AtriCure, Inc. (ATRC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
AtriCure, Inc. (ATRC) Soars to 52-Week High, Time to Cash Out?
AtriCure (ATRC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Has AtriCure (ATRC) Outpaced Other Medical Stocks This Year?
Here is how AtriCure (ATRC) and Ensign Group (ENSG) have performed compared to their sector so far this year.
AtriCure (ATRC) Is Up 6.32% in One Week: What You Should Know
Does AtriCure (ATRC) have what it takes to be a top stock pick for momentum investors? Let's find out.
ATRC Treats First Patients Using Novel Dual-Energy PFA-RFA Platform
AtriCure's first patients treated with its dual-energy PFA-RFA platform mark a key step as it moves toward a clinical trial next year.
Are Medical Stocks Lagging AtriCure (ATRC) This Year?
Here is how AtriCure (ATRC) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Is AtriCure Stock a Buy or Sell After a Director Dumped 10,000 Shares?
AtriCure Board of Directors member Sven Wehrwein sold 10,000 shares in the company on Nov. 24 and 25, 2025. The transaction was valued at nearly $377,000.
Wall Street Analysts Believe AtriCure (ATRC) Could Rally 36.3%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 36.3% in AtriCure (ATRC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
